NI201500074A - Trans-4-{2-[4-(2, 3-diclorofenil)-piperazin-1-il]-etil}-n, n-dimetilcarbamoil-ciclohexilamina para el tratamiento de síntomas negativos de la esquizofrenia. - Google Patents

Trans-4-{2-[4-(2, 3-diclorofenil)-piperazin-1-il]-etil}-n, n-dimetilcarbamoil-ciclohexilamina para el tratamiento de síntomas negativos de la esquizofrenia.

Info

Publication number
NI201500074A
NI201500074A NI201500074A NI201500074A NI201500074A NI 201500074 A NI201500074 A NI 201500074A NI 201500074 A NI201500074 A NI 201500074A NI 201500074 A NI201500074 A NI 201500074A NI 201500074 A NI201500074 A NI 201500074A
Authority
NI
Nicaragua
Prior art keywords
schizophrenia
negative symptoms
dimethylcarbamoyl
cyclohexylamine
piperazin
Prior art date
Application number
NI201500074A
Other languages
English (en)
Inventor
György Pitter János
Szatmári Balázs
Debelle Marc
József Németh György
Laszlovszky István
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of NI201500074A publication Critical patent/NI201500074A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a trans-4-{2-[4-(2, 3-diclorofenil)-piperazin-1-il]-etil}-N, N-dimetilcarbamoil-ciclohexilamina (cariprazina) y a sus sales farmacéuticamente aceptables, hidratos, solvatos y polimorfos para su uso en el tratamiento de síntomas negativos primarios de la esquizofrenia y/o síntomas predominantemente negativos de la esquizofrenia.
NI201500074A 2012-11-29 2015-05-27 Trans-4-{2-[4-(2, 3-diclorofenil)-piperazin-1-il]-etil}-n, n-dimetilcarbamoil-ciclohexilamina para el tratamiento de síntomas negativos de la esquizofrenia. NI201500074A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1200691A HU231227B1 (hu) 2012-11-29 2012-11-29 Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére

Publications (1)

Publication Number Publication Date
NI201500074A true NI201500074A (es) 2015-09-18

Family

ID=70289034

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500074A NI201500074A (es) 2012-11-29 2015-05-27 Trans-4-{2-[4-(2, 3-diclorofenil)-piperazin-1-il]-etil}-n, n-dimetilcarbamoil-ciclohexilamina para el tratamiento de síntomas negativos de la esquizofrenia.

Country Status (36)

Country Link
US (1) US20150306094A1 (es)
EP (2) EP2925324B1 (es)
JP (2) JP2016501215A (es)
KR (2) KR20210010955A (es)
CN (1) CN104812390A (es)
AP (1) AP2015008448A0 (es)
AU (1) AU2013350819B9 (es)
BR (1) BR112015012512A2 (es)
CA (1) CA2890952A1 (es)
CL (1) CL2015001468A1 (es)
CR (1) CR20150244A (es)
CY (1) CY1123766T1 (es)
DK (1) DK2925324T3 (es)
EA (1) EA039245B1 (es)
ES (1) ES2863052T3 (es)
GE (1) GEP20186849B (es)
HK (1) HK1212608A1 (es)
HR (1) HRP20210486T1 (es)
HU (2) HU231227B1 (es)
IL (1) IL238723B (es)
LT (1) LT2925324T (es)
MD (2) MD4865C1 (es)
MX (2) MX2015006677A (es)
MY (1) MY174663A (es)
NI (1) NI201500074A (es)
NZ (1) NZ708295A (es)
PE (1) PE20151052A1 (es)
PH (1) PH12015501124B1 (es)
PL (1) PL2925324T3 (es)
PT (1) PT2925324T (es)
RS (1) RS61509B1 (es)
SG (1) SG11201503672SA (es)
SI (1) SI2925324T1 (es)
UA (1) UA123492C2 (es)
WO (1) WO2014083522A1 (es)
ZA (1) ZA201503660B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192507A1 (en) 2008-07-16 2013-08-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
HU231173B1 (hu) * 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Ipari eljárás cariprazine előállítására
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
WO2019016828A1 (en) * 2017-07-15 2019-01-24 Msn Laboratories Private Limited, R&D Center NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N- {4- [2- [4- (2,3-DICHLOROPHENYL) PIPERAZIN-1-YL] ETHYL] CYCLOHEXYL} -N ', N'-DIMETHYLUMED HYDROCHLORIDE AND POLYMORPHS THIS ONE
US20200375983A1 (en) * 2017-12-01 2020-12-03 Aurobindo Pharma Ltd A process for the preparation of cariprazine hydrochloride
WO2020056929A1 (zh) * 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11344503B2 (en) 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HU230748B1 (hu) 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
HUP0700369A2 (en) 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
KR20100022955A (ko) * 2007-05-24 2010-03-03 리히터 게데온 닐트. (티오) -카르바모일-시클로헥산 유도체 및 정신분열 치료 방법
WO2010126527A1 (en) 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders

Also Published As

Publication number Publication date
US20150306094A1 (en) 2015-10-29
AP2015008448A0 (en) 2015-05-31
KR102314248B1 (ko) 2021-10-19
HRP20210486T1 (hr) 2021-05-14
KR20150088270A (ko) 2015-07-31
JP2019163240A (ja) 2019-09-26
EA201500575A1 (ru) 2015-09-30
CY1123766T1 (el) 2022-05-27
PE20151052A1 (es) 2015-08-09
JP2016501215A (ja) 2016-01-18
HUE054054T2 (hu) 2021-08-30
PL2925324T3 (pl) 2021-06-28
MD4865C1 (ro) 2024-02-29
GEP20186849B (en) 2018-05-10
HUP1200691A1 (es) 2014-06-30
MX2015006677A (es) 2015-08-10
EP3653211A1 (en) 2020-05-20
MX2021000342A (es) 2021-04-13
NZ708295A (en) 2020-03-27
CA2890952A1 (en) 2014-06-05
SI2925324T1 (sl) 2021-04-30
ES2863052T3 (es) 2021-10-08
EA039245B1 (ru) 2021-12-22
AU2013350819B9 (en) 2018-06-21
UA123492C2 (uk) 2021-04-14
HK1212608A1 (zh) 2016-06-17
MD20150058A2 (ro) 2015-11-30
PT2925324T (pt) 2021-02-16
IL238723B (en) 2020-02-27
WO2014083522A1 (en) 2014-06-05
PH12015501124A1 (en) 2015-08-03
CR20150244A (es) 2015-06-23
AU2013350819B2 (en) 2018-05-31
HU231227B1 (hu) 2022-03-28
EP2925324A1 (en) 2015-10-07
MD4865B1 (ro) 2023-07-31
MD20200089A2 (ro) 2021-05-31
AU2013350819A1 (en) 2015-06-04
EP2925324B1 (en) 2020-12-30
DK2925324T3 (da) 2021-03-01
CN104812390A (zh) 2015-07-29
IL238723A0 (en) 2015-06-30
RS61509B1 (sr) 2021-03-31
ZA201503660B (en) 2016-03-30
SG11201503672SA (en) 2015-06-29
LT2925324T (lt) 2021-02-25
BR112015012512A2 (pt) 2017-07-11
MY174663A (en) 2020-05-05
KR20210010955A (ko) 2021-01-28
PH12015501124B1 (en) 2015-08-03
CL2015001468A1 (es) 2015-08-07

Similar Documents

Publication Publication Date Title
NI201500074A (es) Trans-4-{2-[4-(2, 3-diclorofenil)-piperazin-1-il]-etil}-n, n-dimetilcarbamoil-ciclohexilamina para el tratamiento de síntomas negativos de la esquizofrenia.
MA39749A (fr) Dérivés de pipéridine-dione
AU2014267235A8 (en) Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
CU20140109A7 (es) Compuestos heterocíclicos
MA40171A (fr) Dérivés d'azamophinan et leur utilisation
NI200900202A (es) Metabolitos de derivados del (tio) - carbamoil - ciclohexano.
CY1119425T1 (el) Ενωσεις φαινοξυαιθυλο πιπεριδινης
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
AR094935A1 (es) Tosilato de n-hidroxi-4-{2-[3-(n,n-dimetilaminometil)benzofuran-2-ilcarbonil-amino]etoxi}benzamida (abexinostat)
CY1118886T1 (el) Θεραπευτικες χρησεις της 1-[2-(2,4-διμεθυλ-φαινυλσουλφανυλ)φαινυλ]πιπεραζινης
CO2019008110A2 (es) Activador de nrf2
CL2012001641A1 (es) Compuestos derivados de piperazina; composición farmacéutica; que comprende a uno de los compuestos y uso de los compuestos en la preparación de medicamentos para el tratamiento y/o prevención de infecciones por protozoos, en forma particular para el tratamiento y/o prevención de la malaria.
CY1121313T1 (el) Φαρμακευτικη διεργασια και ενδιαμεσα
FR2977492B1 (fr) Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
RU2013110799A (ru) Средство для профилактики и лечения диабета
TH167866A (th) ทรานส์-4-{2-[4-(2,3-ไดคลอโรเฟนิล)-พิเพอร์แอซิน-1-อิล]-เอธิล}-n,n- ไดเมธิลคาร์บามออิล-ไซโคลเฮกซิล แอมีน สำหรับการบำบัดอาการทางลบ ของโรคจิตเภท
CR20150059A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CU20090190A7 (es) Sales novedosas de piperazina como antagonistas d3/d2
UY33228A (es) La aplicación de bacteiras del ácido láctico para el tratamiento o la prevención de la rinitis
DOP2009000032A (es) Derivados de feniloxianilina